NZ528624A - Antibodies against cancer - Google Patents
Antibodies against cancerInfo
- Publication number
- NZ528624A NZ528624A NZ528624A NZ52862402A NZ528624A NZ 528624 A NZ528624 A NZ 528624A NZ 528624 A NZ528624 A NZ 528624A NZ 52862402 A NZ52862402 A NZ 52862402A NZ 528624 A NZ528624 A NZ 528624A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- cancer
- fragment
- monoclonal
- antibodies against
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR3958A AUPR395801A0 (en) | 2001-03-26 | 2001-03-26 | Antibodies against cancer |
| PCT/AU2002/000362 WO2002077033A1 (en) | 2001-03-26 | 2002-03-26 | Antibodies against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ528624A true NZ528624A (en) | 2006-03-31 |
Family
ID=3827964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ528624A NZ528624A (en) | 2001-03-26 | 2002-03-26 | Antibodies against cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7318924B2 (OSRAM) |
| EP (1) | EP1383801A4 (OSRAM) |
| JP (2) | JP4854912B2 (OSRAM) |
| KR (1) | KR100909290B1 (OSRAM) |
| CN (2) | CN101310770A (OSRAM) |
| AU (3) | AUPR395801A0 (OSRAM) |
| CA (1) | CA2442318A1 (OSRAM) |
| NZ (1) | NZ528624A (OSRAM) |
| WO (1) | WO2002077033A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| SK14432003A3 (sk) | 2001-04-26 | 2004-07-07 | Biogen, Inc. | Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| AU2003301619A1 (en) * | 2002-10-23 | 2004-05-13 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| EP1624073A4 (en) * | 2003-04-03 | 2006-05-17 | Oncorex Inc | DRUG |
| WO2005000898A2 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| CA2539116C (en) * | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| EP2311880A3 (en) * | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
| US7939056B2 (en) * | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| EP2162152A2 (en) * | 2007-06-01 | 2010-03-17 | Biogen Idec MA, Inc. | Cripto binding molecules |
| EP2303319B1 (en) | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| KR100973029B1 (ko) * | 2008-10-07 | 2010-08-11 | 박지운 | 알루미늄 합금 가로등 등주 |
| CN102272157B (zh) * | 2008-11-07 | 2015-11-25 | 研究发展基金会 | 用于抑制cripto/grp78复合物形成和信号的组合物和方法 |
| JP5990752B2 (ja) * | 2011-01-31 | 2016-09-14 | オリンパス株式会社 | 抗体療法の効果増強剤 |
| TWI582112B (zh) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二） |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| AU2016250900B2 (en) * | 2015-04-20 | 2022-03-17 | GlyTherix Ltd. | Therapeutic antibodies and uses thereof |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CA2990300A1 (en) | 2015-06-23 | 2016-12-29 | Hans-Georg Lerchen | Site specific homogeneous conjugates with ksp inhibitors |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| DE69738868D1 (de) | 1996-05-22 | 2008-09-11 | Viventia Biotech Inc | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| ID29246A (id) | 1999-03-11 | 2001-08-16 | Ardenia Investments Ltd | Senyawa-senyawa baru untuk pengobatan kanker |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) * | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| AU9272401A (en) | 2000-09-18 | 2002-03-26 | Biogen Inc | Cripto mutant and uses thereof |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| SK14432003A3 (sk) | 2001-04-26 | 2004-07-07 | Biogen, Inc. | Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie |
-
2001
- 2001-03-26 AU AUPR3958A patent/AUPR395801A0/en not_active Abandoned
-
2002
- 2002-03-26 US US10/470,013 patent/US7318924B2/en not_active Expired - Fee Related
- 2002-03-26 CN CNA2008101103851A patent/CN101310770A/zh active Pending
- 2002-03-26 CN CNB028073177A patent/CN100457781C/zh not_active Expired - Fee Related
- 2002-03-26 EP EP02706533A patent/EP1383801A4/en not_active Withdrawn
- 2002-03-26 AU AU2002240719A patent/AU2002240719B2/en not_active Ceased
- 2002-03-26 JP JP2002576291A patent/JP4854912B2/ja not_active Expired - Fee Related
- 2002-03-26 CA CA002442318A patent/CA2442318A1/en not_active Abandoned
- 2002-03-26 NZ NZ528624A patent/NZ528624A/xx not_active IP Right Cessation
- 2002-03-26 WO PCT/AU2002/000362 patent/WO2002077033A1/en not_active Ceased
-
2003
- 2003-09-26 KR KR1020037012528A patent/KR100909290B1/ko not_active Expired - Fee Related
-
2007
- 2007-04-11 AU AU2007201587A patent/AU2007201587A1/en not_active Abandoned
-
2008
- 2008-07-22 JP JP2008188842A patent/JP2009024014A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN100457781C (zh) | 2009-02-04 |
| AUPR395801A0 (en) | 2001-04-26 |
| US20040176576A1 (en) | 2004-09-09 |
| CN101310770A (zh) | 2008-11-26 |
| KR20040010613A (ko) | 2004-01-31 |
| US7318924B2 (en) | 2008-01-15 |
| AU2007201587A1 (en) | 2007-05-03 |
| WO2002077033A1 (en) | 2002-10-03 |
| CA2442318A1 (en) | 2002-10-03 |
| KR100909290B1 (ko) | 2009-07-24 |
| JP2009024014A (ja) | 2009-02-05 |
| AU2002240719B2 (en) | 2007-01-11 |
| EP1383801A1 (en) | 2004-01-28 |
| JP4854912B2 (ja) | 2012-01-18 |
| EP1383801A4 (en) | 2005-06-01 |
| CN1639194A (zh) | 2005-07-13 |
| JP2004534741A (ja) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ528624A (en) | Antibodies against cancer | |
| RU2008128244A (ru) | Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2 | |
| IL161686A (en) | Use of a soluble monoclonal antibody that specifically binds trail receptor dr5 in the manufacture of pharmaceutical compositions targeting cells expressing dr5 | |
| JP2003503361A5 (OSRAM) | ||
| UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| WO2004032857A3 (en) | Antibody therapy | |
| JP2004534741A5 (OSRAM) | ||
| WO2004010947A3 (en) | Humanized antibodies against human 4-1bb | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| ZA200609407B (en) | Monoclonal antibodies to hepatocyte growth factor | |
| NZ568769A (en) | Human monoclonal antibodies against CD20 | |
| NZ572756A (en) | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody | |
| NZ596878A (en) | Methods of administering anti-tnfalpha antibodies | |
| CA2383493A1 (en) | Treating prostate cancer with anti-erbb2 antibodies | |
| NO20091792L (no) | Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff | |
| WO2003099196A3 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
| GEP20084484B (en) | Antibodies to insulin-like growth factor i receptor | |
| TR200102845T2 (tr) | Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
| TW200517124A (en) | Fully human antibodies against human 4-1BB | |
| SI1684770T1 (sl) | Oligo-beta-(1,3)-glukan in monoklonska protitelesa proti raku | |
| WO2024062072A3 (en) | Anti-ccr8 monoclonal antibodies and their therapeutic use | |
| WO2002072008A3 (en) | Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |